Identifying the proper strain of influenza to vaccinate against.
Creating an effective distribution plan.
Creating an effective communication strategy.
Identifying novel strains of the virus.
Effective vaccines offer broad protection against many strains of the virus.
Effective vaccines are easily manufactured.
Effective vaccines are distributed in the areas where pandemics are most likely to occur.
Effective vaccines trigger the human immune system to create antibodies that cripple the virus.
Effective vaccines combine inactive and active virus components.
Successful vaccines have been developed and are being tested.
No successful vaccines have been developed against the most virulent influenza strain.
Successful vaccines have been developed, but problems with manufacturing are interfering with effective delivery.
Successful vaccines have not yet been developed, but scientists are confident that one will be found soon.
A successful vaccine requiring two doses has been developed, but a single dose vaccine is still being worked on.
The H5N1 influenza strain has not been isolated.
The H9N2 influenza strain does not behave like other influenza strains.
The H5N1 influenza strain exhibits properties that scientists have never seen before.
Scientists do not know very much about the H5N1 influenza strain.
To date, candidate vaccines have not been able to trigger the immune system very well.
Overcoming constraints on manufacturing capacities.
Developing candidate vaccines that do not require an egg white culture.
Development of effective containment for isolated virus strains.
The development and testing of candidate vaccines.
Developing successful predictors for the most likely pandemic strains.
The scientific community is adequately prepared to deal with an avian influenza pandemic.
The work being done now will be completed in time to prevent a world heath disaster.
The pandemic strain may not target segments of the population that are typically vulnerable to known influenza strains.
The successful candidate vaccine will require a minimum of two doses per person.
Inactivated vaccines are most likely to be successful against avian influenza strains.
The Federal approval process for a new vaccine.
Atypical vulnerabilities among the human population.
An avian influenza outbreak that kills 40% of the world's poultry population.
Political unrest in Asia.
Idle vaccine manufacturing capacity.